Literature DB >> 19267386

Discoidin domain receptor 2 mediates the collagen II-dependent release of interleukin-6 in primary human chondrocytes.

Andreas R Klatt1, Dagmar Zech, Gertrud Kühn, Brigitte Paul-Klausch, Gabriele Klinger, Joerg H Renno, Joachim Schmidt, Gebhart Malchau, Klaus Wielckens.   

Abstract

We deciphered constituent parts of a signal transduction cascade that is initiated by collagen II and results in the release of various pro-inflammatory cytokines, including interleukin-6 (IL-6), in primary human chondrocytes. This cascade represents a feed-forward mechanism whereby cartilage matrix degradation is exacerbated by the mutually inducing effect of released collagen II fragments and pro-inflammatory cytokines. We previously proposed discoidin domain receptor 2 as a central mediator in this event. Since this cascade plays a prominent role in the pathogenesis of osteoarthritis, our study further investigates the hypothesis that discoidin domain receptor 2 is a candidate receptor for collagen II, and that transcription factor NFkappaB, lipid kinase PI3K, and the MAP kinases are constituent parts of this very signal transduction cascade. To accomplish this, we selectively knocked down the molecules of interest in primary human chondrocytes, induced the specified cascade by incubating primary human chondrocytes with collagen II, and observed the outcome, specifically the changes in interleukin-6 release. Knockdown was performed by siRNA-mediated gene silencing in the case of discoidin domain receptor 2 (DDR2) or by using specific inhibitors for the remainder of the molecules. Results indicated that discoidin domain receptor 2 mediates the collagen II-dependent release of interleukin-6 in primary human chondrocytes and that MAP kinases p38, JNK and ERK, as well as transcription factor NFkappaB, are integral components of intracellular collagen II signalling. Given the detrimental role of these molecules in osteoarthritis, our findings provide new targets for more specific therapeutics, which may have fewer side effects than those currently applied.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19267386     DOI: 10.1002/path.2529

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

1.  Intact pericellular matrix of articular cartilage is required for unactivated discoidin domain receptor 2 in the mouse model.

Authors:  Lin Xu; Ilona Polur; Jacqueline M Servais; Sirena Hsieh; Peter L Lee; Mary B Goldring; Yefu Li
Journal:  Am J Pathol       Date:  2011-09       Impact factor: 4.307

Review 2.  Targeting Discoidin Domain Receptor 2 for the Development of Disease-Modifying Osteoarthritis Drugs.

Authors:  Li Xiao; Chenlu Liu; Beiyu Wang; Wei Fei; Yandong Mu; Lin Xu; Yefu Li
Journal:  Cartilage       Date:  2019-06-10       Impact factor: 3.117

3.  Discoidin domain receptor 2 germline gene deletion leads to altered heart structure and function in the mouse.

Authors:  Randy T Cowling; Seon Ju Yeo; In Jai Kim; Joong Il Park; Yusu Gu; Nancy D Dalton; Kirk L Peterson; Barry H Greenberg
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-03       Impact factor: 4.733

4.  New findings in osteoarthritis pathogenesis: therapeutic implications.

Authors:  Lia Pulsatelli; Olga Addimanda; Veronica Brusi; Branka Pavloska; Riccardo Meliconi
Journal:  Ther Adv Chronic Dis       Date:  2013-01       Impact factor: 5.091

Review 5.  Immunopathogenesis of osteoarthritis.

Authors:  Abdul Haseeb; Tariq M Haqqi
Journal:  Clin Immunol       Date:  2013-01-06       Impact factor: 3.969

6.  Anticytokine therapy for osteoarthritis: evidence to date.

Authors:  Charles J Malemud
Journal:  Drugs Aging       Date:  2010-02-01       Impact factor: 3.923

7.  Potential association of DCBLD2 polymorphisms with fall rates of FEV(1) by aspirin provocation in Korean asthmatics.

Authors:  Tae-Joon Park; Jeong-Hyun Kim; Byung-Lae Park; Hyun Sub Cheong; Joon Seol Bae; Charisse F Pasaje; Jong-Sook Park; Soo-Taek Uh; Mi-Kyeong Kim; Inseon S Choi; Choon-Sik Park; Hyoung Doo Shin
Journal:  J Korean Med Sci       Date:  2012-03-21       Impact factor: 2.153

8.  A hexadecylamide derivative of hyaluronan (HYMOVIS®) has superior beneficial effects on human osteoarthritic chondrocytes and synoviocytes than unmodified hyaluronan.

Authors:  Margaret M Smith; Amy K Russell; Antonella Schiavinato; Christopher B Little
Journal:  J Inflamm (Lond)       Date:  2013-07-27       Impact factor: 4.981

9.  Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.

Authors:  Leo K Iwai; Leo S Payne; Maciej T Luczynski; Francis Chang; Huifang Xu; Ryan W Clinton; Angela Paul; Edward A Esposito; Scott Gridley; Birgit Leitinger; Kristen M Naegle; Paul H Huang
Journal:  Biochem J       Date:  2013-09-15       Impact factor: 3.857

10.  Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model.

Authors:  Anika I Tsuchida; Michiel Beekhuizen; Marijn Rutgers; Gerjo J V M van Osch; Joris E J Bekkers; Arjan G J Bot; Bernd Geurts; Wouter J A Dhert; Daniel B F Saris; Laura B Creemers
Journal:  Arthritis Res Ther       Date:  2012-12-03       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.